James Paul Lang - 02 Jan 2026 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Reporting relationship: Director
Issuer ticker: HALO
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 18:56:43 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ James R. Oehler, Attorney-in-Fact

Key filing fact

James Paul Lang filed Form 4 for HALOZYME THERAPEUTICS, INC. (HALO) on 06 Jan 2026.

Key facts

This page summarizes James Paul Lang's Form 4 filing for HALOZYME THERAPEUTICS, INC. (HALO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 18:56.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001703090 Primary reporting owner

Lang James Paul

Relationship: Director
Address: 12390 EL CAMINO REAL, SAN DIEGO
Signature: /s/ James R. Oehler, Attorney-in-Fact
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HALO transaction

Restricted Stock Units

Award

Transaction value: $0
Shares: +889
Change %
Price: $0.000000
Shares after: 889
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HALO transaction Derivative

Option to Purchase Common Stock

Award

Transaction value: $0
Shares: +1,342
Change %
Price: $0.000000
Shares after: 1,342
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,342
Exercise price: $70.31
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2026 annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Footnote F2

Represents a stock options granted under the Issuer director compensation program. This grant will vest in full on the date of the Issuer 2026 annual meeting of stockholders.